Qiagen (NYSE:QGEN), a German provider of sample and assay technologies, has received emergency use authorisation for a new COVID-19 test from the US drugs regulator FDA, Reuters news agency reported on Monday.
The company was quoted as stating: "This polymerase chain reaction (PCR) multiplex test will be an important tool now and in upcoming winter seasons for simultaneous qualitative detection and differentiation of influenzas A and B, respiratory syncytial virus (RSV) and SARS-CoV-2 infections within 80 minute."
AstraZeneca's Trixeo Aerosphere approved in EU for asthma maintenance treatment
Insmed's ARIKAYCE sNDA granted priority review by FDA
Precigen announces FDA platform technology designation for AdenoVerse
Kelun-Biotech publishes phase III data for trastuzumab botidotin in HER2-positive breast cancer
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Akeso presents positive results from registrational Phase III study of ivonescimab
Insilico Medicine doses first patient in Phase III trial of rentosertib
Altesa BioSciences presents positive vapendavir clinical data at ERS International Congress 2026
Akeso's ivonescimab meets overall survival endpoint in interim analysis of Phase III HARMONi-2 study
AstraZeneca completes global licence agreement for Zegfrovy
Kazia Therapeutics reports 100% clinical benefit rate in initial paxalisib breast cancer trial
Oxcia receives EMA orphan designation for OXC-201 in idiopathic pulmonary fibrosis
Cizzle Bio presents CIZ1B biomarker blood test for lung cancer at Next Generation Dx Summit
Maverix Medical's Narwhal Cryo System receives FDA 510(k) clearance